Preserving Patient Access to Compounded Medications Act of 2019
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 28, 2019)
Preserving Patient Access to Compounded Medications Act of 2019
This bill addresses regulations governing compounding pharmacies.
The bill expands the circumstances under which a drug may be compounded (i.e., manufactured at small scale) to allow pharmacists and physicians to compound drugs for administration to patients in an office or clinical setting, in accordance with state law. (Compounded drugs are not required to meet certain federal requirements regarding manufacturing, labeling, or approval.)
Dietary supplements may be used in the compounding of a drug.
The bill exempts from interstate distribution limits the dispensing of a compounded drug from the facility where it is compounded to a patient or health facility.
The bill limits the scope of Food and Drug Administration (FDA) inspections of compounding pharmacies to certain equipment, materials, containers, and labeling. This aligns the scope of inspections of compounding pharmacies with the scope of inspections of other pharmacies. (Currently, the scope of inspections of compounding pharmacies is the same as the scope of inspections of drug manufacturers.)
The bill also eliminates the requirement for compounding pharmacies to register with the FDA as drug manufacturers.What just happenedMar 29, 2019
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 28, 2019
- Mar 29, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 28, 2019IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Mar 28, 2019IntroReferralIntro-H
Introduced in House
- Mar 28, 2019IntroReferral1000
Introduced in House